LAVE Voices Opinion On Venezuelan Pricing Debacle

7 August 1994

In the light of the arrests made recently in the Venezuelan pharmaceutical industry concerning overpricing of medicines (Marketletter August 1), the industry association representing the national pharmaceutical companies, LAVE, has informed the Marketletter of its version of the sequence of events leading to the arrests.

LAVE says that for around three years the Ministry for Public Works (Fomento) in Venezuela and the pharmaceutical industry have reached agreements on the pricing of medicines in the free market. In many cases prices remained stable for around six months, it says.

The most recent agreement between the two covered the period from August 1, 1993 to November 30, 1993. The industry raised its prices in line with inflation as calculated by the Venezuelan central bank for the previous month. The inflation index for the five-month period was: July 3.1%; August 3.1%; September 3.3%; October 5.0%; and November 3.6%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight